Frontiers in Neuroscience (Jul 2024)

Systems genetics identifies methionine as a high risk factor for Alzheimer's disease

  • Congmin Wang,
  • Yu Hei,
  • Yu Liu,
  • Yu Liu,
  • Akhilesh Kumar Bajpai,
  • Yuhe Li,
  • Yawen Guan,
  • Fuyi Xu,
  • Fuyi Xu,
  • Cuifang Yao,
  • Cuifang Yao

DOI
https://doi.org/10.3389/fnins.2024.1381889
Journal volume & issue
Vol. 18

Abstract

Read online

As a dietary strategy, methionine restriction has been reported to promote longevity and regulate metabolic disorders. However, the role and possible regulatory mechanisms underlying methionine in neurodegenerative diseases such as Alzheimer's disease (AD), remain unexplored. This study utilized the data from BXD recombinant inbred (RI) mice to establish a correlation between the AD phenotype in mice and methionine level. Gene enrichment analysis indicated that the genes associated with the concentration of methionine in the midbrain are involved in the dopaminergic synaptic signaling pathway. Protein interaction network analysis revealed that glycogen synthase kinase 3 beta (GSK-3β) was a key regulator of the dopaminergic synaptic pathway and its expression level was significantly correlated with the AD phenotype. Finally, in vitro experiments demonstrated that methionine deprivation could reduce the expression of Aβ and phosphorylated Tau, suggesting that lowering methionine levels in humans may be a preventive or therapeutic strategy for AD. In conclusion, our findings support that methionine is a high risk factor for AD. These findings predict potential regulatory network, theoretically supporting methionine restriction to prevent AD.

Keywords